| __timestamp | HUTCHMED (China) Limited | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 91813000 | 122045000 |
| Thursday, January 1, 2015 | 178203000 | 144427000 |
| Friday, January 1, 2016 | 216080000 | 215003000 |
| Sunday, January 1, 2017 | 241203000 | 302238000 |
| Monday, January 1, 2018 | 214109000 | 408897000 |
| Tuesday, January 1, 2019 | 204890000 | 392755000 |
| Wednesday, January 1, 2020 | 227976000 | 520397000 |
| Friday, January 1, 2021 | 356128000 | 579775000 |
| Saturday, January 1, 2022 | 426409000 | 667238000 |
| Sunday, January 1, 2023 | 837999000 | 607521000 |
Cracking the code
In the competitive landscape of pharmaceuticals, revenue growth is a key indicator of success. Over the past decade, HUTCHMED (China) Limited and Supernus Pharmaceuticals, Inc. have been vying for dominance. From 2014 to 2023, HUTCHMED's revenue surged by an impressive 813%, peaking in 2023. Meanwhile, Supernus Pharmaceuticals experienced a steady climb, with a 398% increase, reaching its zenith in 2022.
HUTCHMED's revenue trajectory highlights its strategic expansion in the Chinese market, with a notable leap in 2023, surpassing Supernus for the first time. Supernus, on the other hand, maintained a consistent upward trend, driven by its innovative product line in the U.S. market.
As both companies continue to innovate, the revenue race remains unpredictable. Investors and industry watchers should keep a close eye on their next moves.
Revenue Insights: Eli Lilly and Company and HUTCHMED (China) Limited Performance Compared
Merck & Co., Inc. and Supernus Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Annual Revenue Comparison: BioMarin Pharmaceutical Inc. vs HUTCHMED (China) Limited
Revenue Insights: Catalent, Inc. and Supernus Pharmaceuticals, Inc. Performance Compared
Breaking Down Revenue Trends: Walgreens Boots Alliance, Inc. vs HUTCHMED (China) Limited
Ascendis Pharma A/S and Supernus Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Annual Revenue Comparison: Pharming Group N.V. vs HUTCHMED (China) Limited
Revenue Showdown: PTC Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
Perrigo Company plc and Supernus Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Vericel Corporation or HUTCHMED (China) Limited: Who Leads in Yearly Revenue?
Who Generates More Revenue? HUTCHMED (China) Limited or Travere Therapeutics, Inc.
Breaking Down Revenue Trends: ImmunityBio, Inc. vs Supernus Pharmaceuticals, Inc.